Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Assets: 2012-2025

Historic Non-Current Assets for RedHill Biopharma (RDHL) over the last 1 years, with Jun 2025 value amounting to $5.8 million.

  • RedHill Biopharma's Non-Current Assets fell 7.93% to $5.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year decrease of 7.93%. This contributed to the annual value of $6.1 million for FY2024, which is 11.22% down from last year.
  • As of Q2 2025, RedHill Biopharma's Non-Current Assets stood at $5.8 million, which was down 5.09% from $6.1 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Non-Current Assets peaked at $105.2 million during Q2 2021, and registered a low of $5.8 million during Q2 2025.
  • Its 3-year average for Non-Current Assets is $6.6 million, with a median of $6.3 million in 2024.
  • Data for RedHill Biopharma's Non-Current Assets shows a maximum YoY crashed of 90.53% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Non-Current Assets stood at $92.0 million in 2021, then dropped by 20.72% to $73.0 million in 2022, then tumbled by 90.53% to $6.9 million in 2023, then decreased by 11.22% to $6.1 million in 2024, then fell by 7.93% to $5.8 million in 2025.
  • Its Non-Current Assets was $5.8 million in Q2 2025, compared to $6.1 million in Q4 2024 and $6.3 million in Q2 2024.